VNRX, US9286612067

VolitionRx stock: VolitionRx grants 12,000 RSUs to marketing chief

Published on 10/24/2026 at 01:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The award includes 6,681 prior RSUs due to vest on January 9, 2027. VolitionRx stock has 419 units due to forfeit under the same plan.

Equity awards shape the update

On October 21, 2026, Ann-Louise Batchelor received 12,000 RSUs.
The filing says 6,681 earlier RSUs vest on January 9, 2027.
VolitionRx announced a USD 7.5 million note prepayment on September 14, 2026.

VNRX, US9286612067, Illustration mit AI erstellt.

VolitionRx Limited (ISIN US9286612067) granted Group Chief Marketing Officer Ann-Louise Batchelor 12,000 restricted stock units on October 21, 2026, according to StockTitan. The award vests in full on January 9, 2027, subject to continued service.

What changes with the award?

The filing gives the grant a wider context: 6,681 of 7,100 previously issued restricted stock units are also scheduled to vest on January 9, 2027, while 419 units are due to be forfeited. Batchelor was listed with 27,786 securities held directly and 1,471 shares held indirectly by her spouse after the adjustment.

The award followed a one-for-20 reverse stock split completed on April 28, 2026. That corporate action adjusted outstanding equity awards and changed the share count used in the filing.

Three dated steps for VolitionRx

The company timeline places three quantified events in order. On September 14, 2026, VolitionRx announced full prepayment of a USD 7.5 million senior secured convertible promissory note. On September 17, 2026, it detailed the DETECSEPS program launch in France. On October 21, 2026, the company granted 12,000 restricted stock units to its marketing chief.

What dates matter next?

The next dated equity event is January 9, 2027, when the 12,000 new units and 6,681 earlier units are scheduled to vest, subject to continued service. VolitionRx describes its business as developing blood tests for earlier detection and monitoring of cancer and diseases associated with NETosis, including sepsis, in its investor-relations materials.

Stock context and company profile

VolitionRx is listed on the NYSE under VNRX and operates in healthcare medical devices. The company says its research and development activities span Belgium, the United States, London and Singapore, while its commercial pipeline includes tests for cancer and NETosis-related diseases.